+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07815886

Evaluating Long-Term Real-World Use of Benralizumab in Adults with Eosinophilic Granulomatosis with Polyangiitis EGPA The BELONG-EGPA Study

Led by European EGPA Study Group · Updated on 2026-09-11

100

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term real-world safety and effectiveness of benralizumab in adult patients diagnosed with eosinophilic granulomatosis with polyangiitis EGPA. This observational study includes patients treated at specialized EGPA centers within the European EGPA Study Group. The study involves adults meeting specific diagnostic criteria who receive benralizumab and have at least 3 months of follow-up data available. Participants receive benralizumab at a dose of 30 mg every 4 weeks. The study collects clinical, laboratory, lung function, treatment, relapse, and safety information from medical records at baseline and at 3, 6, 12, and 24 months after starting treatment. The study also compares outcomes between patients receiving benralizumab as first-line biologic therapy and those previously treated with mepolizumab. Dosage changes and adverse events will be recorded during follow-up. During the study, researchers review data on disease activity, lung function changes, relapses, treatment persistence, corticosteroid use, and adverse events. Data are collected through standardized electronic reports from the patients medical charts. The total follow-up period is up to 24 months, with assessments at multiple scheduled intervals. All information is anonymized and stored centrally to ensure patient confidentiality.

CONDITIONS

Brief Title

Benralizumab Effectiveness in EGPA

Research Team

G

Giacomo Emmi, MD/PhD

I

Irene Mattioli, PharmD/PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here